Global Omalizumab Monoclonal Antibody Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Omalizumab Monoclonal Antibody Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Omalizumab Monoclonal Antibody Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Omalizumab Monoclonal Antibody Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Persistent Asthma and Nasal Polyps are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Omalizumab Monoclonal Antibody Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Omalizumab Monoclonal Antibody Biosimilars key manufacturers include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. Roche, Novartis, Glenmark Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Omalizumab Monoclonal Antibody Biosimilars can be divided into 150 mg/mL and 75 mg/0.5 mL, etc. 150 mg/mL is the mainstream product in the market, accounting for % sales share globally in 2022.
Omalizumab Monoclonal Antibody Biosimilars is widely used in various fields, such as Persistent Asthma, Nasal Polyps and Chronic Idiopathic Urticaria,, etc. Persistent Asthma provides greatest supports to the Omalizumab Monoclonal Antibody Biosimilars industry development. In 2022, global % sales of Omalizumab Monoclonal Antibody Biosimilars went into Persistent Asthma filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Omalizumab Monoclonal Antibody Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Omalizumab Monoclonal Antibody Biosimilars market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Omalizumab Monoclonal Antibody Biosimilars, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Omalizumab Monoclonal Antibody Biosimilars industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Omalizumab Monoclonal Antibody Biosimilars in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Omalizumab Monoclonal Antibody Biosimilars introduction, etc. Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Omalizumab Monoclonal Antibody Biosimilars market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Omalizumab Monoclonal Antibody Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Omalizumab Monoclonal Antibody Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Persistent Asthma and Nasal Polyps are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Omalizumab Monoclonal Antibody Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Omalizumab Monoclonal Antibody Biosimilars key manufacturers include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. Roche, Novartis, Glenmark Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Omalizumab Monoclonal Antibody Biosimilars can be divided into 150 mg/mL and 75 mg/0.5 mL, etc. 150 mg/mL is the mainstream product in the market, accounting for % sales share globally in 2022.
Omalizumab Monoclonal Antibody Biosimilars is widely used in various fields, such as Persistent Asthma, Nasal Polyps and Chronic Idiopathic Urticaria,, etc. Persistent Asthma provides greatest supports to the Omalizumab Monoclonal Antibody Biosimilars industry development. In 2022, global % sales of Omalizumab Monoclonal Antibody Biosimilars went into Persistent Asthma filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Omalizumab Monoclonal Antibody Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Omalizumab Monoclonal Antibody Biosimilars market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Omalizumab Monoclonal Antibody Biosimilars, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Omalizumab Monoclonal Antibody Biosimilars industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Omalizumab Monoclonal Antibody Biosimilars in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Omalizumab Monoclonal Antibody Biosimilars introduction, etc. Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Omalizumab Monoclonal Antibody Biosimilars market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices